Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of idelalisib in preparation of medicine for treating hepatic fibrosis diseases

A liver fibrosis and drug technology, which is applied in the application field of Adeleris in the preparation of drugs for the treatment of liver fibrosis, can solve the problems of inhibiting tumor cell chemotaxis and adhesion, reducing cancer cell viability, etc.

Active Publication Date: 2020-10-30
TIANJIN JIKUN MEDICAL TECH CO LTD
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Treatment of Lymphoma with Adelaris Inhibits Chemotaxis and Adhesion of Tumor Cells and Reduces Cancer Cell Viability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of idelalisib in preparation of medicine for treating hepatic fibrosis diseases
  • Application of idelalisib in preparation of medicine for treating hepatic fibrosis diseases
  • Application of idelalisib in preparation of medicine for treating hepatic fibrosis diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Effects of Aldelaris on Carbon Tetrachloride-Induced Liver Fibrosis in Mice

[0022] Preparation of liver fibrosis animal model: take C57BL / 6J, (age 8-10 weeks) wild-type mice, give the mice intraperitoneal injection anesthesia with a mass fraction of 10% chloral hydrate at 0.5mL / 100g (body weight), and anesthetize The mice were weighed and recorded and injected intraperitoneally with 20% 1ml / kg carbon tetrachloride (olive oil as solvent), 3 times / week for 8 weeks.

[0023] Grouping situation: the control group was intraperitoneally injected with the same volume of olive oil; the model group was modeled according to the above method, and the corresponding solvent olive oil was injected intraperitoneally from the first day after carbon tetrachloride treatment until the end of the experiment; From the 29th day to the 56th day of carbon tetrachloride treatment, the test ended. The low-dose group was given 30 mg / kg Idelaris to the mice by intragastric administration every d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of idelalisib in preparation of a medicine for treating hepatic fibrosis diseases. Wherein the structure of the idelalisib is shown as the following formula (I),and the research shows that the idelalisib has a good effect on liver fibrosis, has no adverse reaction, can slow down mouse liver fibrosis induced by carbon tetrachloride, and has a good applicationprospect in the aspects of treating, relieving or improving liver fibrosis diseases.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to the application of Adelaris in the preparation of drugs for treating liver fibrosis. Background technique [0002] Liver fibrosis is a chronic liver injury caused by multiple factors, the main causes are chronic HCV and HBV infection, alcoholic liver disease, nonalcoholic steatohepatitis (NASH), primary biliary cirrhosis, primary cirrhosis cholangitis, autoimmune hepatitis, etc. Studies have found that the pathological changes of extracellular matrix (ECM) in liver tissue during liver fibrosis are caused by the disorder of the homeostasis mechanism that controls the formation and degradation of ECM. Excessive ECM formation or reduced degradation for any reason can lead to excessive deposition of ECM. When the liver is injured, damaged hepatocytes, immune cells and activated Kupffer cells release pro-fibrotic factors, which transform the hepatic stellate cells from a static st...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/52A61P1/16
CPCA61K31/52A61P1/16
Inventor 杨诚周红刚李霄鹤张亮李建伦东超
Owner TIANJIN JIKUN MEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com